REFERENCES
- Anderson, K. M., Lee, F. H. & Mizai, K. 1970. Effects of androgen in vivo on some properties of isolated rat ventral prostate nuclei. Exp Cell Res 61, 371.
- Burton, K. 1956. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62, 315.
- Fosså, S. D. & Miller, A. 1976. Treatment of advanced carcinoma of the prostate with estramustine phosphate. J Urol 115, 406.
- Godefroi, V. C. & Brooks, S. C. 1973. Improved gel-filtration method for analysis of estrogen receptor binding. Analyt Biochem 51, 335.
- Høisaeter, P. A. 1973. The androgen cytosol receptor in the ventral prostate of the rat. Methodological problems. Biochem Biophys Acta 317, 492.
- Høisaeter, P. A. 1974. Studies on hormone-cytostatic complexes in the cytoplasm of rat prostatic gland. Invest Urol 12, 33.
- Høisaeter, P. A. 1975a. Incorporation of 3H-thymidine into rat ventral prostate in organ culture. Influence of hormone-cytostatic complexes. Invest Urol 12, 479.
- Høisaeter, P. A. 1975b. The effect of oestradiol-3N-bis(2-chloro-ethyl) carbamate-17β-phosphate (Estracyt®) on the 5α-reductase in the rat ventral prostate. Acta Endocr (Kbh) 80, 188.
- Høisaeter, P. A. 1976a. Studies on the conversion of estradiol linked to a cytostatic agent (Estracyt®) in various rat tissues. Acta Endocr 82, 661.
- Høisaeter, P. A. 1976b. Incorporation of 3H-thymidine and 14C-amino acids into ventral prostate after in vivo treatment with estradiol-3N-bis(2-chloroethyl) carbamate-17β-phosphate (Estracyt®) and its estrogen and cytostatic parts. Invest Urol, in press.
- Jønsson, G. & Høgberg, B. 1971. Treatment of advanced prostatic carcinoma with Estracyt®. A preliminary report. Scand J Urol Nephrol 5, 103.
- Kirdani, R. Y., Müntzing, J., Varkarakis, M. J., Murphy, G. P. & Sandberg, A. A. 1974. Studies on the anti-prostatic action of Estracyt®, a nitrogen mustard of estradiol. Cancer Res 34, 1031.
- Klungsøyr, L. 1969. Quantitative estimation of protein. Separation of alkaline protein-copper complex from excess copper on Sephadex G-25. Analyt Biochemistry 27, 91.
- Lindberg, B. 1972. Treatment of rapidly progressing prostatic carcinoma with Estracyt®. J Urol 108, 303.
- Mainwaring, W. I. P. 1974. In Steroid-cell interactions (ed. R. J. B.King and W. I. P.Mainwaring), p. 22. Butterworths, London.
- Nilsson, T. & Müntzing, J. 1973. Histochemical and biochemical investigation of advanced prostatic carcinoma treated with estramustine phosphate, Estracyt®. Scand J Urol Nephrol 7, 18.
- Plym-Forshell, G. & Nilsson, H. 1974. The distribution of radioactivity after administration of labelled estramustin phosphate (Estracyt®) estradiol-17β-phosphate and estradiol-17β to rats. Acta Pharmacol Toxicol, Suppl. 1, 35, p. 28.
- Szendrøi, Z., Kocsar, L., Karika, Zs., Fuzi, M., Tarjan, Gy., Reischl, Gy. & Eckhardt, S. 1973. Recent data on the mechanism of action of estrogens in the treatment of prostatic tumor patients. Internat Urol Nephrol 5, 311.
- Tritsch, G. L., Shukla, S. K., Mittelmann, A. & Murphy, G. P. 1974. Estracyt® (NSC-89199) as a substrate for serum phosphatases. Invest Urol 12, 38.
- van Beurden-Lamers, W. M. O., Brinkmann, A. O., Mulder, E. & van der Molen, H. J. 1974. High-affinity binding of estradiol-17β by cytosols from tests interstitial tissue, pituitary, adrenal, liver and accessory sex glands of the male rat. Biochem J 140, 495.